ARVINAS, INC. (ARVN) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-03-19

Key Insights

Noah Berkowitz, the Chief Medical Officer of Arvinas, Inc. (ARVN), sold 6,435 shares of common stock on March 18, 2026 at an average price of $11.1004 per share.
The sale was made automatically by the company to cover tax withholding obligations in connection with the vesting and settlement of 25% of Berkowitz's restricted stock units (RSUs) granted on March 18, 2024.
This transaction does not represent a discretionary trade by the reporting person, but rather a routine stock sale to satisfy tax obligations related to equity compensation.

Want the newest filings?

This analysis covers the filing from 2026-03-19. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-03-09

Briggs Morrison, a director of Arvinas, Inc., purchased 20,000 shares of the company's common stock on March 6, 2026 at a weighted average price of $13.4035 per share.
This insider buying activity suggests that Morrison has a positive outlook on the company's future prospects and is willing to invest his own capital in Arvinas.
The amount of shares purchased represents a meaningful transaction, indicating Morrison's confidence in the company's long-term growth potential.

Other reports for ARVINAS, INC.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.